Companies: 10,795·Total market cap: $144.5T
Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc.

AXSMNASDAQHealthcare● Active
$232.32
+$0.84(+0.36%)
Market Cap$12.0B
P/E Ratio
52W High$242.41
52W Low$96.09

Axsome Therapeutics, Inc. (AXSM) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

axsm · stock forecast · 25 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 25 Wall Street analysts in the past 3 months

SellBuy

Buy

25 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
24
Hold
1
Sell
0
Strong Sell
0
Total: 25 · Buy rate: 96.0%

12-Month Price Target

High

$302

Consensus

$256

+10.1% upside

Low

$200

Median: $259.5 · Last Close: $232.32

The Axsome Therapeutics, Inc. (AXSM) analyst consensus is Buy, based on ratings from 25 Wall Street analysts over the past 3 months. The average 12-month AXSM price target is $255.81, representing +10.1% upside from the current price of $232.32.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $256 (10.1%)

Consensus Target

$255.81

10.1% upside

High Target

$302

30.0%

Low Target

$200

-13.9%

Current Price

$232.32

as of today

Based on analyst price targets, the AXSM stock price prediction for the next 12 months ranges from $200 to $302. The consensus AXSM price forecast of $255.81 implies 10.1% upside from the current price of $232.32.

Short-Term Price Prediction

Bull

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$232.450.06%

1-day model range: $231.01–$233.9. Peak: $233.9 (+0.06%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$318+36.8%
2028$394+69.6%
2029$455+96.0%
2030$501+115.8%
2031+130.0%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

93%7%0%
13Buy
1Neutral
0Sell
RSI (14)55.4Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · AXSM · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$229.94BUY
MA 10$232.17BUY
MA 20$229.66BUY
MA 50$203.18BUY
MA 100$188.39BUY
MA 200$162.30BUY
Current $AXSM · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$231.34BUY
EMA 10$230.80BUY
EMA 20$226.30BUY
EMA 50$209.29BUY
EMA 100$191.43BUY
EMA 200$169.18BUY
Current $AXSM · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Guggenheim2026-05-05
Maintains
BuyBuy
Mizuho2026-05-05
Maintains
OutperformOutperform
Baird2026-05-05
Maintains
OutperformOutperform
HC Wainwright & Co.2026-05-05
Maintains
BuyBuy
Morgan Stanley2026-05-05
Maintains
Equal WeightEqual Weight
Wells Fargo2026-05-05
Maintains
OverweightOverweight
RBC Capital2026-05-05
Maintains
OutperformOutperform
Needham2026-05-05
Maintains
BuyBuy
HC Wainwright & Co.2026-05-04
Maintains
BuyBuy
Jefferies2026-05-04
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Axsome Therapeutics, Inc. (AXSM) stock. Of the recent 215 rating actions, 4 were upgrades and 2 were downgrades. 25 analysts currently cover AXSM.

Analyst Recommendation Trends

Buy ratings110↑ +9
Hold ratings01↑ +1
Sell ratings00

AXSM analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 10 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$984M

↓ 56.8% YoY

Revenue Next Year

$1.6B

↑ 60.5% YoY

EPS This Year

$-1.96

EPS Next Year

$5.52

↓ 381.5% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast AXSM EPS of $-1.96 for the current fiscal year, based on estimates from 12 analysts. The AXSM revenue forecast is $984M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The AXSM stock forecast is supported by two independent data sources: analyst consensus ratings from 25 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus AXSM price target is $255.81 (+10.1% upside), with an analyst consensus of Buy.

The AXSM short-term stock prediction for tomorrow is $232.45 (+0.06%). The AXSM stock price prediction for 2027 estimates an average of $318. The AXSM stock prediction for 2030 projects a range of $467–$535.

Axsome Therapeutics, Inc. trades on NASDAQ under the ticker AXSM. The AXSM stock outlook for 2027 is broadly positive, supported by a Buy consensus among 96% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

AXSM forecast · 8 questions

According to 25 Wall Street analysts, the average 12-month AXSM price target is $255.81, with a high forecast of $302.00 and a low of $200.00. The median price target is shown in the chart above when available. This implies +10.1% potential upside from the current price of $232.32.

AXSM price targetWhat is AXSM price targetAXSM analyst price targetAXSM 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.